Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Inclusion Criteria:

- Patients who have completed selected ongoing or planned trials with FTY720.

Exclusion Criteria:

- Premature permanent discontinuation of a previous fingolimod study.

- Pregnant or nursing (lactating) women.

- Women of child-bearing potential, UNLESS they are using two birth control methods, at
least 1 of which must be hormonal contraception, tubal sterilization, partner's
vasectomy or intrauterine device.

- Chronic disease of the immune system, other than multiple sclerosis, which may require
immunosuppressive treatment.

- Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or
proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c > 8%.

- Active systemic bacterial, viral or fungal infections, or known to have AIDS,
Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface
antigen or Hepatitis C antibody tests.

- Previous treatment with cladribine, cyclophosphamide or mitoxantrone.

- Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in
the past 3 months during the previous fingolimod study:

- Any of the following cardiovascular conditions that have developed during the previous
fingolimod study:

- Myocardial infarction within the past 6 months prior to entry in the extension
study or with current unstable ischemic heart disease;

- Cardiac failure (Class III, according to New York Heart Association
Classification) or any severe cardiac disease as determined by the investigator;

- Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g.,
amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)

- History or presence of a third degree AV block

- Proven history of sick sinus syndrome or sino-atrial heart block

- Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon

- Any of the following pulmonary conditions during the previous fingolimod study:

- Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous
fingolimod study)

- Active tuberculosis

- Alcohol abuse, chronic liver disease during the previous fingolimod study.

The patient must have participated in a previous fingolimod trial to be eligible to
participate in this trial.

Other protocol-defined inclusion/exclusion criteria may apply.